Mechanisms of checkpoint inhibition-induced adverse events

Volume: 200, Issue: 2, Pages: 141 - 154
Published: Feb 21, 2020
Abstract
Summary Immune checkpoint inhibition has revolutionized the treatment of several solid cancers, most notably melanoma and non-small-cell lung cancer (NSCLC). Drugs targeting cytotoxic T lymphocyte antigen (CTLA)-4 and programmed cell death 1 (PD-1) have made their way into routine clinical use; however, this has not been without difficulties. Stimulation of the immune system to target cancer has been found to result in a reduction of...
Paper Details
Title
Mechanisms of checkpoint inhibition-induced adverse events
Published Date
Feb 21, 2020
Volume
200
Issue
2
Pages
141 - 154
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.